[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neuropathic-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neuropathic-pain":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,112,0,25,[9,46,74,99,121,147,175,201,240,270,299,323,353,383,407,431,448,472,491,514,538,572,592,618,644],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100645370","phase-2-daily-encapsulated-green-tea-extract-to-mitigate-neuropathic-pain-in-patients-with-established-cancer-associated-neuropathic-pain-100645370",false,"NCT07682324","Daily, Encapsulated, Green Tea Extract to Mitigate Neuropathic Pain in Patients With Established Cancer-Associated Neuropathic Pain","Daily, Encapsulated, Green Tea Extract (GTE) to Mitigate Neuropathic Pain in Patients With Established Cancer-Associated Neuropathic Pain","GTE","Inclusion Criteria:\n\n* 18 years of age or older.\n* Established cancer-associated neuropathic pain.\n* A baseline Douler Neuropathique 4 (DN4) patient-reported neuropathic pain questionnaire score of greater than or equal to 4.\n* A stable pain management medication regimen, with no more than a 10% change in dosage in the past 14 days prior to enrollment.\n* No known allergy to rice or rice flour (basis of placebo).\n\nExclusion Criteria:\n\n* Actively undergoing cancer treatment.\n* Symptoms and\u002For diagnosis of diabetic peripheral neuropathy.\n* Self-describe as consuming more than 3 cups of green tea or matcha beverages on a daily basis.\n* High probability of completing the study and all study-related measures\u002Factivities required by the protocol.","ALL","18 Years",{"count":21,"type":22},20,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The overall objective of this study is to test an intervention of green tea extract (GTE) to mitigate neuropathic pain in patients, specifically cancer survivors, receiving supportive palliative care. The central hypothesis is that daily, oral, encapsulated GTE will mitigate neuropathic pain, as longitudinally measured by the validated Douleur Neuropathique 4 (DN4) and blood protein biomarkers reported to be linked to the development and\u002For chronicity of neuropathic pain.",[28,29],"Neuropathic Pain","Cancer Treatment",[31,16,32],"green tea extract","neuropathic pain","NOT_YET_RECRUITING","2026-08-19",{"date":36,"type":37},"2026-08-21","ACTUAL",{"date":39,"type":22},"2026-09-30",{"date":41,"type":22},"2029-03-01",{"name":43,"class":44},"University of Alabama at Birmingham","OTHER",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":45},"100643267","empowered-relief-for-caregivers-100643267","NCT07636980","Empowered Relief for Caregivers","Empowered Relief for Caregivers (ER-CY): A Co-Designed Brief Intervention to Support Families of Youth With Chronic Pain","ER-CY","Inclusion Criteria:\n\n* Caregiver of a youth with a chronic pain diagnosis (\\>3 months in duration)\n* English speaking\n\nExclusion Criteria:\n\n* Significant psychosocial complexity based on clinical team assessment (e.g., severe depression\u002Fanxiety, unable to tolerate a group setting)",{"count":55,"type":22},80,[57],"NA","This study is testing a new program called Empowered Relief for Caregivers (ER-CY), designed to support caregivers of children and teens who live with chronic pain. ER-CY is a single two-hour class delivered online. It teaches skills for managing the stress of caring for a child in pain and for responding to a child's pain in helpful ways.\n\nUp to 80 caregivers of youth with chronic pain will take part in one ER-CY class and then complete surveys and a short interview over the following three months. The researchers want to learn two things: whether caregivers are willing and able to take part and find the program helpful and satisfying, and whether the program lowers caregiver distress and improves their child's day-to-day functioning. What is learned will help guide future programs and care for youth with chronic pain and their families.",[60,61,62,28,63,64],"Chronic Pain","Musculoskeletal Pain","Fibromyalgia","Complex Regional Pain Syndromes (CRPS)","Abdominal Pain (AP)","2026-08-17",{"date":67,"type":37},"2026-08-20",{"date":69,"type":22},"2026-10",{"date":71,"type":22},"2028-09",{"name":73,"class":44},"Stanford University",{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":18,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":95,"leadSponsor":97,"locationsCount":45},"100613310","pediatric-electrocutaneous-analgesia-for-children-experiencing-neuropathic-pain-100613310","NCT07264920","Pediatric Electrocutaneous Analgesia for Children Experiencing Neuropathic Pain","PEACE-NP","Inclusion Criteria:\n\n* Able to verbalize pain scores\n* Oncology patients with acute and\u002For chronic pain\n\nExclusion Criteria:\n\n* Patients with Implantable Devices\n* Epilepsy\n* Pregnancy\n* A history of myocardial infarction or ischemic heart disease within the past six months\n* History of severe heart arrhythmia or equivalent heart disease\n* Open Wounds or Infections at site of electrode placement\n* A history of intolerance to transcutaneous electronic nerve stimulation","5 Years","26 Years",{"count":84,"type":22},70,[57],"This is a study evaluating the Scrambler Therapy device as a non-invasive treatment for neuropathic pain in pediatric oncology patients with metastatic bone disease. The primary goal is to assess changes in pain intensity and medication use, aiming to improve quality of life and reduce reliance on systemic pain medications.",[28,60],[89,90,32],"pediatric oncology","chronic pain","2026-08-06",{"date":93,"type":37},"2026-08-10",{"date":69,"type":22},{"date":96,"type":22},"2030-01",{"name":98,"class":44},"Johns Hopkins University",{"id":100,"slug":101,"hasResults":12,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":23,"phases":108,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":4},"100649525","effects-and-mechanisms-of-temporal-interference-stimulation-tis-on-neuropathic-pain-100649525","NCT07735975","Effects and Mechanisms of Temporal Interference Stimulation (TIS) on Neuropathic Pain","TIS","Inclusion Criteria:\n\n* IASP diagnosis of peripheral neuropathic pain;\n* At least one month after the onset of pain;\n* At least moderate pain intensity (≥ 3 assessed by VAS or NRS);\n* 18 years or older;\n* Stable medical treatment from 2 weeks before allocation to the end of the trial;\n* Willing to receive TIS treatment and capable of fulfilling clinical assessments.\n\nExclusion Criteria:\n\n* Contradictions to TIS treatment, such as metal implants or seizure;\n* Serious psychiatric disorder (Hamilton Depression Rating Scale score ≥ 35 or Hamilton Anxiety Rating Scale score ≥ 29);\n* Aphasia or cognitive disorders (Mini mental state examination ≤ 24);\n* Severe clinical disorders caused by tumor or other conditions;\n* Severe cardiopulmonary dysfunction or extreme weakness;\n* History of substance abuse (alcohol, drugs).",{"count":107,"type":22},60,[57],"This study employs temporal interference stimulation (tTIS) to investigate the analgesic effects of tTIS on neuropathic pain and monitor changes in neural plasticity, and explore the dynamic relationship between analgesic efficacy and neural plasticity, thereby providing new strategies for the treatment of neuropathic pain.",[28,111],"tTIS","2026-07-29",{"date":114,"type":37},"2026-07-30",{"date":116,"type":22},"2026-08-01",{"date":118,"type":22},"2028-01-31",{"name":120,"class":44},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":122,"slug":123,"hasResults":12,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":23,"phases":131,"briefSummary":132,"conditions":133,"keywords":135,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":139,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":146},"100649432","impact-of-probiotics-on-neuropathy-induced-by-adjuvant-chemotherapy-in-patients-with-colon-cancer-100649432","NCT07733817","Impact of Probiotics on Neuropathy Induced by Adjuvant Chemotherapy in Patients With Colon Cancer.","Impact of Probiotic Supplementation on Neuropathy Induced by Adjuvant Chemotherapy in Patients With Colon Cancer: a Phase III Randomized Study","PROBIOCOL","Inclusion Criteria:\n\n* Patient ≥ 18 years\n* Patient with histologically confirmed stage III adenocarcinoma colon cancer with curative resection\n* Patient with an indication to start adjuvant oxaliplatin-based chemotherapy (FOLFOX 4 or XELOX regimen)\n* ECOG performance status score of 0 or 1\n* Patient must consent to allow the collection of fecal and blood samples during study for further ancillary studies\n* Screening laboratory values must meet the following criteria:\n* Neutrophils ≥ 1500\u002F mm³; Platelets ≥ 100 000\u002F mm³; Hemoglobin ≥ 9.0 g\u002FdL\n* Bilirubin ≤ 1.5 x ULN, AST and ALT ≤ 3 x ULN\n* Serum creatinine ≤ 1.5 x ULN or measured or calculated creatinine ≥ 50 ml\u002Fmin clearance (CrCl) (using the Cockcroft-Gault formula)\n* Patient with French language comprehension\n* Female subject of childbearing potential must have a negative urine or serum pregnancy test within 7 days before study probiotics supplementation start\n* Patient in reproductive age must be willing to use adequate contraception during study probiotics supplementation\n* Patient affiliated to an appropriate social security system\n* Patient has signed informed consent obtained before to any study specific procedures\n\nEnclusion Criteria:\n\n* Patient with any distant metastasis\n* Patient with current peripheral neuropathy of any grade or ongoing treatment prescribed to prevent or treat peripheral neuropathy\n* Patient with hypersensitivity to any ingredients in the composition of the multi-strain formulation and\u002For maltose\n* Patient with history of acute pancreatitis\n* Patient seriously immunosuppressed\n* Patient with history of other malignancy within the previous 3 years (except for appropriately treated in-situ cervix carcinoma and non-melanoma skin carcinoma)\n* Patient using of probiotics or antibiotic treatments within one month before inclusion\n* Patient with chronic inflammatory gastro-intestinal disease\n* Patient with uracilemia ≥ 16 ng\u002Fml\n* Patient with QT\u002FQTc \\> 450 msec for men and \\> 470 msec for women\n* Patient with active infection requiring systemic therapy\n* Patient with personality disorder or any other known progressive psychiatric pathology\n* Patient with neurological previous history with ongoing symptoms (sequelae of head trauma, stroke, multiple sclerosis, epilepsy, neurodegenerative pathology, etc.)\n* Patient with dependence on alcohol and \u002F or drugs\n* Pregnant or lactating woman\n* Simultaneous participation in another clinical study that may compromise the conduct of this study.\n* Patient assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol\n* Patient deprived of liberty or placed under the authority of a tutor",{"count":130,"type":22},130,[57],"The pbjective of this study is to assess the impact of a multi-strain bacteria probiotic OXXYSLAB® on the reduction of oxaliplatin-induced peripheral neuropathy in patients with stage III colon cancer receiving FOLFOX or XELOX regimen in adjuvant treatment, assessed using the oxaliplatin-specific scale of Levi.",[134,28],"Colon Adenocarcinoma",[136,137,138],"FOLFOX","PROBIOTICS","XELOX",{"date":114,"type":37},{"date":141,"type":22},"2026-10-01",{"date":143,"type":22},"2036-04-01",{"name":145,"class":44},"Centre Francois Baclesse",7,{"id":148,"slug":149,"hasResults":12,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":23,"phases":156,"briefSummary":157,"conditions":158,"keywords":160,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":45},"100546738","virtual-reality-vr-self-hypnosis-software-100546738","NCT06398847","Virtual Reality (VR) Self-Hypnosis Software","An Open-label Study of Self-hypnosis Software for Virtual Reality for the Treatment of HIV-associated Chronic Pain - a Development and Usability Study","Patient Eligibility\n\nInclusion Criteria:\n\n* Adults age ≥18\n* Confirmed diagnosis of HIV, currently on a stable antiretroviral regimen ≥ 90 days.\n* Documentation of chronic pain associated with HIV for≥90 days\n* Stable pain management regimen ≥90 days, or no pain treatments ≥90 days\n* Average pain intensity of 3 or greater on the NRS of the mean daily scores reported between Visit 1 and Visit 2\n* Access to the internet via smartphone, computer, or tablet 7. Fluent in English\n* Capable of giving informed consent and willingness to comply with study procedures.\n\nExclusion Criteria:\n\n* A co-occurring medical or psychiatric condition which would make participation in the study or complicate measurement of changes associated with the intervention.\n* Concurrent participation in another investigational protocol for pain treatment\n* A psychiatric disorder, medical condition, or other life circumstance, which in the opinion of the PI, would contraindicate attendance at sessions, or make it unlikely that the participant could successfully complete the study procedures.\n* Current or prior diagnosis of epilepsy, seizure disorder, dementia, migraines, or other neurological conditions contraindicating the use of virtual reality devices.\n* A medical condition predisposing prospective participant to nausea or dizziness 6. Lack of stereoscopic vision or severe hearing impairment\n* Injury to eyes, face, or neck that impedes using the VR device\n* If participant has access to personal VR gear for gaming or other purposes at home, participant fails to agree not to use these personal VR gear during the course of the protocol.\n* Currently pregnant or planning to become pregnant during the study period",{"count":155,"type":22},40,[57],"This single-site study of self-hypnosis software using an off-the-shelf virtual reality (VR) device (OculusGo™) to determine the software's safety, usability, and preliminary efficacy in pain relief for HIV-associated chronic pain patients. This is funded under the i Prism Funding through Mount Sinai Innovations.",[61,28,159],"Neuralgia",[161,162,163,164],"HIV chronic pain","Self-hypnosis","virtual reality software","non-drug treatment for chronic pain","RECRUITING","2026-07-24",{"date":168,"type":37},"2026-07-27",{"date":170,"type":37},"2026-03-26",{"date":172,"type":22},"2027-06-30",{"name":174,"class":44},"Icahn School of Medicine at Mount Sinai",{"id":176,"slug":177,"hasResults":12,"nctId":178,"briefTitle":179,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":12,"sex":18,"minAge":181,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":23,"phases":183,"briefSummary":184,"conditions":185,"keywords":187,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":45},"100597339","phase-1-simultaneous-engagement-of-networks-for-alleviating-pain-senap-100597339","NCT07057206","Simultaneous Engagement of Networks for Alleviating Pain (SENAP)","Inclusion Criteria:\n\n* Age ≥ 22 years\n* Clinical diagnosis of a refractory chronic neuropathic pain syndrome suggestive of deafferentation or central pain. Non-limiting examples of these syndromes are:\n* post-traumatic pain syndromes (e.g. plexopathies, radiation-induced injury)\n* postsurgical pain syndromes (e.g. phantom limb pain, anesthesia dolorosa)\n* postherpetic neuralgia\n* Central pain syndromes (e.g. post-stroke pain, multiple sclerosis pain, post-radiation pain)\n* Greater than 6 months of chronic neuropathic pain\n* Average pain intensity over the past 30 days reported as 6 or greater on a 0-10 numeric rating scale (NRS)\n* Multidisciplinary pain consensus review that establishes\n* Pain is refractory to medical management\n* Pain that is refractory to or unlikely to be altered by less invasive treatment and\n* Pain distribution either does not permit attempts at relief by a targeted nerve block (e.g., post-stroke pain) or such blocks have provided \\\u003C25% relief.\n* Medication doses currently stable (no active titration or drug trials in progress) in the 30 days prior to baseline (immediately pre-surgical) study visit\n* Ability to speak \u002F read English\n* Capable of understanding and providing informed consent (verified if necessary by a standard tool such as the MacArthur Competency Assessment)\n* Women of childbearing age must be on regular use of an accepted contraceptive method(s).\n\nExclusion Criteria:\n\n* Pregnancy, breastfeeding, or unwilling to maintain regular use of contraceptives. Patients who become pregnant after enrollment may be excluded from the study if study procedures may cause risk to the fetus. Patients who become pregnant prior to the surgical implantation will be excluded from the study.\n* Aphasia severe enough to limit the consent process or communication between the investigators and the patient. Patients with mild or recovering aphasia may be considered candidates at the discretion of the PI.\n* Untreated or uncontrolled psychiatric illness (schizophrenia, bipolar disorder, obsessive-compulsive disorder), or personality disorders (e.g. borderline personality disorder) or other neuropsychiatric conditions that the evaluating clinician would recommend exclusion of the patient after neuropsychiatric evaluation.\n* History of seizure disorder and seizure within the last year. Participants with a remote history of epilepsy will need documentation from their neurologist for eligibility.\n* Suicide attempt within 12 months from baseline visit or imminent suicide risk in the judgment of study clinicians.\n* Modified Scale for Suicidal Ideation Score of greater than or equal to 21\n* History of diagnosed substance use disorder in the past 3 years. Benzodiazepines and\u002For opioids prescribed by a physician with use as directed do not count for this criterion. Cannabis\u002Fcannabinoid products will not be considered an exclusion if used under the auspices of a state-sponsored medical cannabis program.\n* Major medical comorbidities increasing the risk of surgery including uncontrolled hypertension, severe diabetes, major organ system failure, need for chronic anticoagulation other than aspirin, active infection, immunocompromised state, or malignancy with \\\u003C 5 years life expectancy.\n* Inability to temporarily stop anticoagulation therapy (approximately 3 weeks total) for surgery and after surgery. Patients taking these medications will need to discuss the need\u002Frisk of continuing these medications with their physicians and the PI or study personnel may contact the treating physician(s) as well to discuss the risks of anticoagulation \u002F antiaggregation therapy discontinuation.\n* MRI (done within one year of the baseline period) with significant abnormalities other than those associated with the neurological disorder causing chronic pain.\n* Implantable hardware not compatible with MRI or with the study or former metal worker that may pose risk from MRI.\n* Previous ablative intracranial surgery for the management of a central pain syndrome.\n* history of other neurosurgical procedures that may interfere with functioning of the device\n* Active, pending, or planned litigation or workman's compensation claim related to the pain\u002Finjury. Current receipt of disability benefits, without a dispute or litigation, is not an exclusion.\n* Requires ongoing or expected diathermy, electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) to treat a chronic condition\n* Allergies or known hypersensitivity to materials in the implanted system (i.e. titanium, polyurethane, silicone, polyetherimide, stainless steel).\n* Any other condition that, in the judgment of the PI or the Data Safety \\& Monitoring Board, significantly increases risk of receiving an implanted neurostimulator.\n* Those who require ongoing monitoring of a disease state by MRI.\n* Inability to target the somatocognitive action network or cingulate opercular network on fMRI","22 Years",{"count":21,"type":22},[25],"This trial is investigating the acceptability and efficacy of PFM-guided cortical stimulation for the treatment of central neuropathic pain.",[28,186],"Postherpetic Neuralgia",[28,188,189,186,190,191],"Post-Traumatic Pain","Post-Surgical Pain","Central Pain Syndrome","Chronic Neuropathic Pain","2026-07-22",{"date":194,"type":37},"2026-07-23",{"date":196,"type":22},"2026-11-01",{"date":198,"type":22},"2030-12",{"name":200,"class":44},"University of Minnesota",{"id":202,"slug":203,"hasResults":12,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":209,"enrollmentInfo":210,"targetDuration":4,"studyType":23,"phases":212,"briefSummary":205,"conditions":214,"keywords":217,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":239},"100647919","phase-3-extended-release-pregabalin-for-the-treatment-of-neuropathic-pain-in-patients-with-diabetic-peripheral-neuropathy-and-postherpetic-neuralgia-100647919","NCT07712913","Extended-release Pregabalin for the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy and Postherpetic Neuralgia","A Phase III, Multicenter, Randomized, Double-blind, Double-dummy, Controlled, Parallel-group, Non-inferiority Clinical Trial to Evaluate the Efficacy and Safety of Extended-release Pregabalin Tablets Compared With Immediate-release Pregabalin Tablets, in the Relief of Neuropathic Pain in Participants With Diabetic Peripheral Neuropathy or Postherpetic Neuralgia.","PRISE","Inclusion Criteria:\n\nThe following criteria must be met for a participant to be included in the study:\n\n1. Participants of either sex, aged 18 to 75 years.\n2. Be able to understand and agree to participate in the study, undergo the procedures, and attend the visits, as indicated by signing the informed consent form approved by the CEP\u002FConep System.\n3. Have a diagnosis of peripheral neuropathic pain associated with:\n\n   * diabetes mellitus (type 1 or 2), with glycated hemoglobin (HbA1c) levels ≤ 11%, documented symptoms of peripheral diabetic neuropathy for at least 6 months, and use of medication for glycemic control at a stable dose for at least 30 days.\n   * postherpetic neuralgia, with pain symptoms for at least 3 months following a skin rash due to an acute episode of herpes zoster.\n4. Presence of neuropathic pain, with an intensity of ≥ 4 on the 11-point DPRS numerical scale (from 0 \"no pain\" to 10 \"worst possible pain\"‡). ‡ Pain intensity ≥ 4 will be confirmed at the initial visit (IV); during the screening\u002Frandomization visit, Participant Diary No. 1 containing the DPRS scales will be provided, in which the participant will record pain intensity daily upon waking and at the end of the day for 7 days (±2 days). The mean value for pain intensity recorded during the Screening\u002FRandomization Phase will be used to confirm eligibility at the initial visit (IV).\n5. Participants who are unable to become pregnant (postmenopausal women, defined as 12 months or more of amenorrhea, or who have undergone surgical sterilization\\*; and men who have undergone vasectomy\\*\\*) OR participants of reproductive potential who agree to use a reliable method of contraception\\*\\*\\*.\n\n   * Female sterilization (undergoing bilateral surgical oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least 6 weeks prior to administration of the investigational drug.\n\n     * Male sterilization at least 6 months prior to screening. \\*\\*\\* If the participant is of childbearing age and decides to participate in the study, they must use or request that their partner use a safe contraceptive method. A safe contraceptive method is defined as the use of at least one of the following: condoms, a diaphragm, and\u002For a hormonal method (estrogenic and\u002For progestogenic) in the form of medication, including oral, vaginal, injectable, transdermal, and intrauterine devices. Only participants who expressly declare themselves exempt from the risk of pregnancy-whether because they do not engage in sexual activity or because they engage in it in a non-reproductive manner-will have the right to participate in the study without the mandatory use of contraceptives. Examples include participants who have undergone a vasectomy, those with an infertile partner, or those practicing total heterosexual abstinence.\n\nThe decision regarding the best contraceptive method to use will be made jointly by the physician and the study participant. If there are any costs involved, the chosen contraceptive method will be provided by the sponsor free of charge for as long as necessary. In addition, condoms with spermicide will be provided to participants at all study visits, when applicable.\n\nExclusion Criteria:\n\nA positive response to any of the following criteria will exclude the participant from the study:\n\n1. The presence of pain unrelated to the primary diagnosis of diabetic peripheral neuropathy or postherpetic neuralgia that could interfere with the evaluation.\n2. Any skin condition that potentially alters sensation in the affected dermatome or area of neuropathic involvement, which could interfere with the assessment.\n3. Having undergone neurosurgical therapy for the treatment of neuropathy.\n4. Current use, or use within the past 7 days, of nerve block therapy and\u002For medications commonly used to treat neuropathic pain (e.g., benzodiazepines, skeletal muscle relaxants, capsaicin, local anesthetics, opioids, memantine), antiepileptic drugs (e.g., carbamazepine, clonazepam, phenytoin, valproic acid, lamotrigine, topiramate, gabapentin), antidepressants (e.g., tricyclics, serotonin reuptake inhibitors, venlafaxine), and potential neurotoxins (e.g., hydroxychloroquine, deferoxamine, thioridazine, vigabatrin).\n5. History of treatment failure or hypersensitivity to pregabalin or gabapentin.\n6. History of neoplastic disease within the past 2 years (excluding basal cell carcinoma), neurological disease, unstable heart disease, psychiatric conditions (particularly suicidal ideation), and\u002For infection with hepatitis B, hepatitis C, or HIV.\n7. Current laboratory abnormalities in liver enzymes (elevated AST and\u002For ALT 2.5 times the upper limit of the reference range) and\u002For renal insufficiency (glomerular filtration rate \\\u003C 60 mL\u002Fmin\u002F1.73 m²).\n8. History of illicit drug abuse in the past 2 years.\n9. History of alcoholism (average alcohol intake exceeding 3 standard drinks\\* per day or more than 7 standard drinks per week for women, and exceeding 4 standard drinks per day or more than 14 standard drinks per week for men) in the past 2 years.\n\n   \\* A standard drink is: a can of regular beer (330 mL at 4%); a shot of distilled spirits (30 mL at 40%); a glass of wine or a small glass of sherry (100 mL at 12% or 70 mL at 18%); a small glass of liqueur or similar (50 mL at 25%) (53).\n10. Being pregnant, breastfeeding, or intending to become pregnant during the study period.\n11. Having participated in clinical studies in the past 12 (twelve) months, unless there may be a direct benefit to the study participant, at the investigator's discretion.\n12. Having any condition that prevents participation, at the investigator's discretion.","75 Years",{"count":211,"type":22},348,[213],"PHASE3",[215,28,216],"Diabetic Neuropathy","Neuralgia, Postherpetic",[218,219,220,221,222,223,224,225,226,227,228],"multicenter","randomized","double-blind","double-dummy","controlled","parallel-group","non-inferiority","diabetic","postherpetic neuralgia","peripheral neuropathy","Pregabalin","2026-07-13",{"date":231,"type":37},"2026-07-20",{"date":233,"type":37},"2026-06-18",{"date":235,"type":22},"2027-06-01",{"name":237,"class":238},"Brainfarma Industria Química e Farmacêutica S\u002FA","INDUSTRY",15,{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":247,"enrollmentInfo":248,"targetDuration":4,"studyType":23,"phases":249,"briefSummary":250,"conditions":251,"keywords":255,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":45},"100647169","high-intensity-peripheral-magnetic-stimulation-in-traumatic-peripheral-nerve-injury-100647169","NCT07705490","High-Intensity Peripheral Magnetic Stimulation in Traumatic Peripheral Nerve Injury","Clinical and Electrophysiological Evaluation of the Effect of High-Intensity Peripheral Magnetic Stimulation in Traumatic Peripheral Nerve Injury: A Randomized, Double-Blind, Sham-Controlled Trial","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* Traumatic peripheral nerve injury\n* Unilateral traumatic peripheral neuropathy confirmed by electromyography (EMG)\n* Nerve injury occurring at least 3 months prior\n* Douleur Neuropathique 4 (DN4) score ≥ 4\n* Visual Analog Scale (VAS) score ≥ 4\n* Manual Muscle Testing score \\\u003C 5\n* No analgesic use, or stable analgesic therapy for the past month (no dose changes)\n\nExclusion Criteria:\n\n* Active infection or malignancy\n* Metal implant or shrapnel in the application area\n* Electronic implants (e.g., cardiac pacemaker, spinal cord stimulator, deep brain stimulator)\n* Central nervous system diseases\n* Non-traumatic causes of neuropathy (e.g., radiculopathy, diabetic neuropathy, entrapment neuropathies, HIV-related neuropathy, trigeminal neuralgia)\n* Complete nerve injury\n* Injury involving three or more peripheral nerves or plexus injury\n* History of peripheral nerve surgery or injection within the past 3 months\n* Active psychiatric illness\n* Coagulopathy","65 Years",{"count":155,"type":22},[57],"Traumatic peripheral nerve injury is a common cause of chronic neuropathic pain, muscle weakness, and functional limitation, particularly in young and active individuals. Current conservative and pharmacological treatments often provide incomplete relief or carry side effects. High-intensity peripheral magnetic stimulation (PMS) is a non-invasive method that may help reduce neuropathic pain and support motor recovery, but evidence in traumatic nerve injury is limited.\n\nThis randomized, double-blind, sham-controlled trial aims to evaluate whether high-intensity PMS, added to a standardized therapeutic exercise program, improves pain, function, quality of life, and electrophysiological measures in adults with traumatic peripheral nerve injury. Participants will be randomly assigned to receive either active PMS or sham PMS, in addition to the same exercise program. Outcomes will be assessed at baseline, 4 weeks, and 8 weeks.",[252,253,28,254],"Peripheral Nerve Injuries","Traumatic Peripheral Nerve Injury","Peripheral Nerve Injuries, Traumatic",[256,257,28,258,259,260,261],"Peripheral Magnetic Stimulation","High-Intensity Magnetic Stimulation","Nerve Injury","Rehabilitation","Electrophysiology","Sham-Controlled Trial",{"date":263,"type":37},"2026-07-15",{"date":265,"type":22},"2026-08",{"date":267,"type":22},"2027-07",{"name":269,"class":44},"Gaziler Physical Medicine and Rehabilitation Education and Research Hospital",{"id":271,"slug":272,"hasResults":12,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":276,"eligibilityCriteria":277,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":209,"enrollmentInfo":278,"targetDuration":4,"studyType":23,"phases":280,"briefSummary":282,"conditions":283,"keywords":285,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":298},"100645942","phase-4-crisugabalin-in-nmosd-neuropathic-pain-a-randomized-double-blind-placebo-controlled-exploratory-trial-100645942","NCT07699770","Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial","Efficacy and Safety of Crisugabalin in Treating Neuropathic Pain Related to Neuromyelitis Optica Spectrum Disorders: a Multicenter, Prospective, Randomized, Double-blind, Placebo-controlled, Exploratory Trial","TERMINATOR","\\*\\*Inclusion Criteria:\\*\\*\n\nSubjects who meet all of the following criteria will be enrolled in this study:\n\n1. Able to understand and voluntarily sign the written informed consent form;\n2. Male or female aged between 18 years (inclusive) and 75 years;\n3. Diagnosed with aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD) according to the International Panel for NMO Diagnosis (IPND, 2015) criteria;\n4. Patients with comorbid neuropathic pain, DN4 ≥ 4; no change in medication dosage within the past month;\n5. Numeric Rating Scale (NRS) for pain score ≥ 4 at screening;\n6. First-time use of Crisugabalin Capsules.\n\n\\*\\*Exclusion Criteria:\\*\\*\n\nSubjects who meet any of the following criteria will not be enrolled in this study:\n\n1. Presence of peripheral neuropathy or pain unrelated to NMOSD that, in the investigator's judgment, may confound the assessment;\n2. Known history of allergy to the investigational drug components, or to other drugs with similar chemical structures, or to any excipients;\n3. Prior use of pregabalin ≥ 300 mg\u002Fday, gabapentin ≥ 1200 mg\u002Fday, or mirogabalin ≥ 30 mg\u002Fday with lack of clinical efficacy as judged by the investigator;\n4. Severe liver or kidney function abnormalities, meeting any of the following clinical laboratory findings:\n\n1\\) Liver function: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 3 × upper limit of normal (ULN); 2) Estimated glomerular filtration rate (eGFR) \\\u003C 60 mL\u002Fmin\u002F1.73 m² (calculated using the simplified MDRD formula); 5. Women who are pregnant, planning to become pregnant during the study period, or currently breastfeeding; subjects who are unwilling to use reliable contraceptive measures (including condoms, spermicides, intrauterine devices, etc.) from the time of signing the ICF until 28 days after the last dose of the investigational drug; 6. Current use of IL-6 receptor blockers (e.g., tocilizumab, satralizumab); 7. History of suicidal behavior or suicidal ideation; 8. Participation in any other clinical study within 30 days prior to screening; 9. The investigator determines that there are other situations in which participation in the study is inappropriate.",{"count":279,"type":22},110,[281],"PHASE4","This study is a multicenter, prospective, randomized, double-blind, placebo-controlled exploratory investigation conducted in China.",[284,28],"Neuromyelitis Optica Spectrum Disorders (NMOSD)",[286,287,288,289],"neuromyelitis optica spectrum disorders","Neuropathic pain","Crisugabalin","NMOSD","2026-07-09",{"date":229,"type":37},{"date":293,"type":22},"2026-06-15",{"date":295,"type":22},"2027-12-31",{"name":297,"class":44},"Tang-Du Hospital",10,{"id":300,"slug":301,"hasResults":12,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":306,"targetDuration":4,"studyType":23,"phases":308,"briefSummary":309,"conditions":310,"keywords":4,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":45},"100549778","phase-1-novel-soluble-epoxide-hydrolase-inhibitor-for-neuropathic-pain-in-patients-with-spinal-cord-injury-100549778","NCT06438471","Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord Injury","Development of a Novel Soluble Epoxide Hydrolase Inhibitor as a Strategy for Treating Neuropathic Pain in Patients With SCI","Inclusion Criteria:\n\nEach subject must meet all of the following criteria to be enrolled in this study:\n\n1. Male and female subjects must be 18 and older.\n2. Subjects must be willing to provide written informed consent to participate in the study.\n3. Subjects must be able to provide own transportation to study site every day for the duration of the study.\n4. Subjects with either a traumatic or a non-traumatic SCI may be eligible to enroll in this study. For subjects with complete or incomplete traumatic spinal cord injuries (tSCI), or complete non-traumatic spinal cord injury: Subjects must have a complete or incomplete T6 or below tSCI, or complete non-traumatic SCI of at least 12 months duration, with below-level neuropathic pain identified by the International Spinal Cord Injury Pain (ISCIP) classification criteria. Importantly, subjects must not be ventilator-dependent as detailed in Exclusion Criteria 1. For subjects with degenerative partial spinal cord injuries (pSCI): Subjects must have an incomplete, non-traumatic, SCI at any level secondary to degenerative spinal disorders such as disc degeneration, spinal stenosis, or spondylosis, with associated chronic neuropathic pain. The injury and the associated pain must be of at least 12 months duration. Neuropathic pain should meet the ISCIP classification criteria. Importantly, subjects must not be ventilator-dependent as detailed in Exclusion Criteria 1.\n5. Subjects must have completed a minimum of 6 of the 7 daily assessments for average and worst daily pain prior to final screening, using an 11-point numerical rating scale (NRS) for average daily pain intensity, and the arithmetic average daily SCI neuropathic pain score must be ≥4 and ≤9, with a standard deviation less than or equal to 1.2. Daily pain assessment screenings will be done over the phone with the study coordinator after informed consent is obtained.\n6. Subjects must have failed at least 2 classes of medications for their neuropathic pain due to SCI (classes may include antidepressants, antiepileptics, opioids, anti-inflammatories, topical treatments, etc.).\n7. Subjects must be in overall stable condition, as determined by pre-study medical history, physical examination, clinical laboratory tests, and 12 lead ECG measurements\n8. Subjects must have normal or not clinically significant clinical laboratory test results, as determined by the study investigator, including coagulation panel, blood cell counts, comprehensive metabolic panel analytes, and creatinine clearance (60 cm3\u002Fmin or greater). Clinical laboratory tests results that are consistent with known, stable comorbidities will be allowed as long as the comorbidities do not represent an exclusion criteria per se.\n9. Subjects must have a negative screening for HIV, Hepatitis C, and Hepatitis B within 30 days of randomization.\n10. Subjects must have a normal hypothalamic-pituitary-adrenal and hypothalamic-pituitary-gonadal axes screening study.\n11. Subjects must have a negative urinary drug screen (UDS) for illicit drugs (marihuana\u002FTHC are allowed) and serum ethanol level \\\u003C80 mg\u002FdL.\n12. Male subjects who are not surgically sterile (vasectomized) and their female sexual partners must agree to use contraception during the study period and for 2 months afterward.\n13. Male subjects must not donate sperm during the study and for 12 months after receiving the last dose of study drug.\n14. Female subjects must be non-pregnant, non-lactating, and either postmenopausal for at least 1 year, or surgically sterile (bilateral tubal ligation ('clipping or tying tubes' or hysterectomy) for at least 3 months, or they must agree to use two forms of highly effective contraception method (less than 1 pregnancy per 100 people using the method for one year), from 28 days and\u002For their last confirmed menstrual period prior to study enrollment (whichever is longer) until 2 months after clinic discharge. Postmenopausal status will be defined as follow: minimum 1 year; amenorrhea duration of 12 consecutive months and a serum FSH value \\>40 IU\u002FL; postmenopausal status must be confirmed by an FSH test at Screening). Highly effective contraception methods include: Intra-uterine device (IUD) containing either copper or levonorgestrel (e.g., Mirena®), and\u002For barrier methods of contraception, including condoms (external or internal) and diaphragm ('cap'). Hormonal methods of contraception (with the exception of hormonal IUD) are not permitted within this study. Female participants will refrain from using hormonal contraceptives for at least 28 days prior to study entry until the end of the study period. Participants\u002FParticipant's partner(s) must also use a barrier form of contraception, from the first dose of study drug through until 2 months after the last dose. For all females of childbearing potential, the pregnancy test result must be negative at Screening and Pre-Study Baseline (Day -1).\n15. Subjects must be able to speak, read, and understand English sufficiently to allow comprehension and completion of all study assessments.\n\nExclusion Criteria:\n\nSubjects meeting any of the following criteria will be excluded from the study:\n\n1. Ventilator-dependent subjects, with the exception of nocturnal use of CPAP or BiPAP.\n2. Subjects with pain that is not present every day (chronic) or where the pain description does not have a classic neuropathic phenotype.\n3. Subjects with other chronic neuropathic pain conditions, including painful diabetic neuropathy, HIV-associated neuropathic pain, chemotherapy or ethanol-associated neuropathy.\n4. Subjects with other pain syndromes that may confound assessment or self-evaluation of the SCI neuropathic pain.\n5. Subjects with only negative symptoms, defined as numbness without clear evidence of spontaneous pain, either constant or episodic.\n6. Non-opioid pain medications will be allowed if at a fixed stable dose for more than 1 month prior to Screening with no anticipation of the dose changing during the study, and if they do not interfere with the subject's ability to rate pain as per Investigator's discretion. Allowed non-opioid medications include gabapentin, pregabalin, duloxetine, acetaminophen, ibuprofen, celecoxib, meloxicam, other antidepressants including amitriptyline and other antiepileptics, as well as topical capsaicin and topical lidocaine.\n7. Subjects using opioid medications will be required to be on a dose of 60 morphine milligrams equivalents (MME) per day or less, and with a stable dose for at least four (4) weeks prior to consent, with no anticipation of dose changing during the study.\n8. Subjects with active Hepatitis A, Hepatitis B and\u002For Hepatitis C.\n9. Subjects with any clinically unstable or significant cardiovascular (including acute coronary syndrome within the prior year to Screening), renal, hepatic, respiratory, gastrointestinal, hematological, endocrine, or infectious disease (including HIV infection).\n10. Subjects with clinically significant abnormalities on screening vital signs, laboratory tests, and\u002For ECG. Subjects with poor venous access will also be excluded.\n11. Subjects with a history of disorders of the hypothalamic-pituitary-adrenal axis, including adrenal insufficiency and Cushing's, or with a history of disorders of the hypothalamic-pituitary-gonadal axis, including hypogonadism.\n12. Subjects who have used any topical, oral, or intravenous exogenous corticosteroids within 12 weeks and\u002For intra-articular exogenous corticosteroids within 6 months prior to the start of the trial, or who plan on using them during the study.\n13. Subjects who have used fludrocortisone or exogenous testosterone products within 12 weeks prior to the start of the trial or who plan on using them during the study.\n14. Subjects who have used (within 14 of randomization) or plan on using during the duration of the study any renin-angiotensin system (RAS)-acting drugs (including angiotensin-receptor blockers, or ARBs; angiotensin-converting enzyme inhibitors, or ACE-inhibitors; and direct renin inhibitors) or mineralocorticoid receptor antagonists (such as spironolactone and eplerenone)\n15. Subjects who have used chemotherapy agents, or who have a personal history of cancer or cancer in first degree relatives suggestive of elevated cancer risk, other than nonmetastatic skin cancer that has been completely excised, within 5 years prior to Screening.\n16. Subjects with a history of bacterial, fungal, or viral infection requiring treatment with antibiotics, antifungal agents, or antivirals within 1 month prior to randomization.\n17. Subjects who have used (within 14 days of randomization) or plan on using during the duration of the study any prescription or over-the-counter drugs that are moderate-strong CYP3A4 inducers or inhibitors.\n18. Subjects who have used (within 14 days of randomization) or plan on using during the duration of the study any dietary aids, supplements, or foods that are moderate-strong CYP3A4 inhibitors (e.g., grapefruit juice).\n19. Subjects with difficulty in swallowing oral medications.\n20. Subjects with serious psychosocial comorbidities as determined by the Investigator.\n21. Subjects with current cognitive or major psychiatric disorders, or any other condition that could interfere with compliance with study procedures.\n22. Subjects with a positive drug or alcohol test (\\>80 mg\u002FdL) during Screening and\u002For admission (a positive THC test will be allowed as long as it consists of minimal social use, per discretion of Investigator), or with a recent history of binge drinking within 1 week of randomization.\n23. Subjects who have used any other investigational drug within 1 month prior to enrollment. If the investigational drug is known to have a long half-life, a longer washout period will be done.\n24. Subjects with a presence or history of active gastrointestinal disorder, including esophageal or gastroduodenal ulceration, or renal, hepatic, or coagulant disorder within 1 month prior to enrollment.\n25. Subjects with a family history of significant cardiac disease (i.e., sudden death in first degree relative; myocardial infarction before the age of 50).\n26. Subjects with confirmed COVID-19, or suspected COVID-19 (e.g., developed symptoms of a respiratory infection such as cough, sore throat, shortness of breath, or fever, but did not get tested for COVID 19) within 30 days of randomization.\n27. Subjects who have received a COVID-19 vaccine within 30 days of randomization or are planning on receiving it during the study duration.\n28. Exclude subjects with spinal cord injury at T6 or higher with a history of neurogenic bladder.\n29. Exclude subjects with documented autonomic dysreflexia (AD) or a history of episodes consistent with undiagnosed AD as determined by an experienced clinician.",{"count":307,"type":22},36,[25],"The goal of this clinical trial is to evaluate safety and tolerability of multiple oral doses of EC5026 in male and female patients with neuropathic pain due to traumatic or non-traumatic (degenerative) spinal cord injury. The main question it aims to answer is whether EC5026 is safe and well tolerated in SCI patients with neuropathic pain. In addition, this trial will also study the effects of EC5026 on pain.\n\nResearchers will compare EC5026 to placebo.\n\nParticipants will be asked to:\n\n* Take EC5026 or placebo in a masked fashion, once daily, for 14 consecutive days.\n* Undergo physical exams, vital signs assessments, ECGs, and blood draws\n* Complete assessments of pain, sleep, functional status, and perception of change",[311,28,312,313,314],"Spinal Cord Injuries","Degenerative Disc Disease","Spinal Stenosis","Spondylosis",{"date":316,"type":37},"2026-07-10",{"date":318,"type":37},"2026-05-01",{"date":320,"type":22},"2027-12",{"name":322,"class":238},"EicOsis Human Health Inc.",{"id":324,"slug":325,"hasResults":12,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":329,"eligibilityCriteria":330,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":331,"enrollmentInfo":332,"targetDuration":4,"studyType":334,"phases":4,"briefSummary":335,"conditions":336,"keywords":338,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":348,"completionDateStruct":349,"leadSponsor":351,"locationsCount":4},"100646226","predict-dolor-ve-validation-of-a-structured-triage-protocol-for-chronic-pain-100646226","NCT07696676","PREDICT-DOLOR VE: Validation of a Structured Triage Protocol for Chronic Pain","PREDICT-DOLOR VE: Prospective Multicenter Diagnostic Accuracy Study for the Validation of a Rule-Based Clinical Decision Support Tool for Chronic Pain Triage in a Low-Resource Setting in Venezuela","PREDICT-VE","Inclusion Criteria:\n\n* Inclusion Criteria:\n* Age 18 years or older\n* Chronic pain of any etiology with duration of 3 months or longer\n* Ability to complete the PREDICT-DOLOR VE digital assessment battery (with assistance if needed)\n* Attending one of the three participating referral centers during the recruitment period\n* Provision of written informed consent before any study procedure\n\nExclusion Criteria:\n\n* Acute pain with duration less than 3 months\n* Active oncological pain under chemotherapy or radiotherapy protocol (separate evaluation pathway required)\n* Cognitive impairment that prevents completion of self-report instruments, even with assistance\n* Active psychiatric emergency or suicidal ideation at time of assessment\n* Refusal to provide informed consent\n* Participation in another clinical trial that could influence triage outcomes","100 Years",{"count":333,"type":22},120,"OBSERVATIONAL","PREDICT-DOLOR VE is a structured clinical triage protocol for chronic pain that uses five internationally validated pain assessment instruments to help healthcare providers determine the appropriate level of care for patients with chronic pain. The tool operates on a free mobile-friendly platform and generates a four-level recommendation: primary care management, referral to physiatry or neurology, priority specialist evaluation, or evaluation for neurosurgical intervention.\n\nThis study will validate the diagnostic accuracy of the PREDICT-DOLOR VE algorithm by comparing its recommendations with the independent assessment of a panel of three specialists in adult patients with chronic pain (lasting 3 months or longer) across three referral centers in Venezuela. The study aims to determine whether this structured, low-cost approach can help connect patients with the right type of care more quickly and consistently.",[60,337,28],"Pain Management",[339,340,341,342,343,344,345],"chronic pain triage","clinical decision support tool","pain assessment","Venezuela","low-resource setting","interprofessional referral","diagnostic accuracy","2026-07-08",{"date":316,"type":37},{"date":116,"type":22},{"date":350,"type":22},"2027-02-02",{"name":352,"class":44},"Universidad Central de Venezuela",{"id":354,"slug":355,"hasResults":12,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":359,"eligibilityCriteria":360,"healthyVolunteers":12,"sex":18,"minAge":361,"maxAge":4,"enrollmentInfo":362,"targetDuration":4,"studyType":23,"phases":364,"briefSummary":365,"conditions":366,"keywords":368,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":45},"100646540","phase-4-osteoporotic-fracture-and-lidocaine-plaster-5-for-neuropathic-pain-prevention-100646540","NCT07691359","Osteoporotic Fracture and Lidocaine Plaster 5% for Neuropathic Pain preventioN","Preventive Effect of 5% Lidocaine Plaster on the Development of Neuropathic Pain Following Osteoporotic Vertebral Fracture: A Proof-of-concept, Controlled, Randomized Trial","FLYNN","Inclusion Criteria:\n\n* Male or female participant aged 50 years or older.\n* Diagnosis of osteoporosis established by the treating rheumatologist.\n* Osteoporotic vertebral fracture diagnosed within the previous month.\n* Pain intensity of ≥3 on a numerical rating scale at the fracture site.\n* Able and willing to provide written informed consent.\n* Affiliated with a French health insurance system.\n\nExclusion Criteria:\n\n* Medical or surgical condition considered by the investigator to be incompatible with study participation.\n* Known hypersensitivity to lidocaine, any excipient of the study treatment, or other amide-type local anesthetics.\n* Current treatment with Class I antiarrhythmic agents (e.g., tocainide, mexiletine) or other local anesthetics.\n* Inflamed or damaged skin at the intended application site (e.g., active herpes zoster lesions, dermatitis, or wounds).\n* Pregnant or breastfeeding women.\n* Women of childbearing potential not using an effective contraceptive method.\n* Positive urine pregnancy test for women whose menopausal status cannot be confirmed.\n* Participation in another clinical research study.\n* Individuals under legal protection or deprived of liberty.\n* Refusal to participate.","50 Years",{"count":363,"type":22},30,[281],"Osteoporotic vertebral fractures may lead to chronic pain with a neuropathic component, which is often underdiagnosed and undertreated in older adults. This proof-of-concept randomized controlled trial aims to evaluate whether early application of a 5% lidocaine plaster can prevent the development of neuropathic pain following an osteoporotic vertebral fracture. Participants will be randomized in a 2:1 ratio to receive either a daily 5% lidocaine plaster plus standard care or standard care alone for 2 months. The primary outcome is the proportion of participants who develop neuropathic pain at 2 months, assessed using the PainDETECT questionnaire.",[367,28],"Osteoporotic Vertebral Fracture",[369,370,371,372,373,374],"Lidocaine 5% Plaster","Lidocaine Patch","Osteoporosis","Pain Prevention","PainDETECT","DN4","2026-07-02",{"date":346,"type":37},{"date":378,"type":22},"2026-07-01",{"date":380,"type":22},"2028-10-01",{"name":382,"class":44},"University Hospital, Clermont-Ferrand",{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":389,"eligibilityCriteria":390,"healthyVolunteers":391,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":392,"targetDuration":4,"studyType":334,"phases":4,"briefSummary":394,"conditions":395,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":403,"leadSponsor":405,"locationsCount":4},"100646660","prevalence-and-risk-factors-for-chronic-post-surgical-pain-following-video-assisted-thoracic-surgery--the-evatho-prospective-bicentric-cohort-study-100646660","NCT07687082","Prevalence and Risk Factors for Chronic Post-Surgical Pain Following Video-Assisted Thoracic Surgery : The EVATHO Prospective Bicentric Cohort Study.","Study of the Prevalence of Chronic Postoperative Pain After Video-Assisted Thoracic Surgery: A Bicentric Cohort Study","EVATHO","Inclusion Criteria:\n\n* Adult patients undergoing video-assisted thoracic surgery (VATS) for thoracic surgery\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Adults under legal protection or unable to provide informed non-opposition\n* Patients unable to understand or complete the study questionnaires\n* Patients not affiliated with a French health insurance scheme.\n* Adults under legal protection, including judicial safeguard, guardianship, or curatorship.\n* Participation in another clinical study involving an ongoing exclusion period.\n* Pregnant or breastfeeding women.",true,{"count":393,"type":22},400,"Chronic post-surgical pain (CPSP) remains a common complication after thoracic surgery and may significantly impair patients' quality of life. Although the widespread adoption of video-assisted thoracic surgery (VATS) has reduced surgical trauma and improved postoperative recovery, a substantial proportion of patients still develop persistent pain.\n\nThe EVATHO study is a multicenter prospective observational cohort designed to determine the prevalence of CPSP three months after VATS and to identify perioperative factors associated with its development. Adult patients undergoing thoracic surgery by VATS at Montpellier and Nice University Hospitals will be prospectively enrolled.\n\nPain intensity, neuropathic pain characteristics, anxiety, depression, quality of life, and analgesic consumption will be assessed using validated questionnaires during the perioperative period and at 1 and 3 months after surgery. The results of this study may help identify patients at increased risk of CPSP and improve perioperative pain management strategies following thoracic surgery.",[396,397,28,398],"Chronic Post-surgical Pain","Postoperative Pain After Thoracic Surgery","Thoracic Surgical Procedures","2026-06-29",{"date":401,"type":37},"2026-07-07",{"date":116,"type":22},{"date":404,"type":22},"2028-08-01",{"name":406,"class":44},"University Hospital, Montpellier",{"id":408,"slug":409,"hasResults":12,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":413,"eligibilityCriteria":414,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":415,"targetDuration":416,"studyType":334,"phases":4,"briefSummary":417,"conditions":418,"keywords":420,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":45},"100638006","hematological-indices-and-sympathetic-block-response-in-neuropathic-pain-100638006","NCT07596823","Hematological Indices and Sympathetic Block Response in Neuropathic Pain","Hematological Inflammatory Indices as Predictors of Treatment Response to Sympathetic Nerve Blocks in Neuropathic Pain: A Prospective Observational Study","HINSPAIN","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosis of neuropathic pain based on clinical evaluation\n* DN4 and\u002For LANSS scores compatible with neuropathic pain\n* Undergoing sympathetic nerve block as part of routine clinical treatment\n* Availability of pre-treatment and follow-up hemogram parameters\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Active infection or acute inflammatory disease\n* Active malignancy\n* History of hematological disease\n* Immunosuppressive therapy or systemic corticosteroid use\n* Major surgery or severe trauma within the last month\n* Pregnancy or breastfeeding\n* Autoimmune or rheumatologic inflammatory disease\n* Missing follow-up data",{"count":333,"type":22},"3 Months","This prospective observational study aims to evaluate the relationship between hematological inflammatory indices and clinical treatment response in patients with neuropathic pain undergoing sympathetic nerve block procedures as part of routine clinical care. Hematological parameters including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), aggregate index of systemic inflammation (AISI), and red cell distribution width (RDW) will be evaluated before and after treatment. The association between changes in these indices and pain outcomes will be analyzed.",[28,419],"Neuropathic Pain Diagnostic Questionnaire (DN4) ≥ 4",[28,421,422],"Sympathetic Nerve","Inflammation","2026-06-25",{"date":399,"type":37},{"date":426,"type":22},"2026-06-01",{"date":428,"type":22},"2027-01-31",{"name":430,"class":44},"Ankara City Hospital Bilkent",{"id":432,"slug":433,"hasResults":12,"nctId":434,"briefTitle":435,"officialTitle":435,"acronym":4,"eligibilityCriteria":436,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":437,"targetDuration":4,"studyType":334,"phases":4,"briefSummary":439,"conditions":440,"keywords":4,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":441,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":446,"locationsCount":45},"100532738","study-of-the-location-of-motor-cortical-stimulation-electrodes-in-chronic-neuropathic-refractory-patients-100532738","NCT06216717","Study of the Location of Motor Cortical Stimulation Electrodes in Chronic Neuropathic Refractory Patients","Inclusion Criteria\n\n* adults\n* patient implanted with a motor cortical stimulation system for chronic neuropathic refractory pain,\n* patient with available postoperative scanner\n\nExclusion Criteria: None",{"count":438,"type":22},100,"Cortical stimulation has been used since 1991 to treat neuropathic pain. However, the underlying mechanisms are still incompletely understood and under-studied. In this protocol, the investigators aim to study the myeloarchitectonic and functional characteristics of areas activated by cortical epidural electrodes and to determine their relation to therapy response in chronic neuropathic refractory pain patients.",[28],{"date":399,"type":37},{"date":443,"type":37},"2023-11-13",{"date":445,"type":22},"2027-06-25",{"name":447,"class":44},"Centre Hospitalier Universitaire de Nice",{"id":449,"slug":450,"hasResults":12,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":4,"eligibilityCriteria":454,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":209,"enrollmentInfo":455,"targetDuration":4,"studyType":23,"phases":457,"briefSummary":458,"conditions":459,"keywords":460,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":470,"locationsCount":45},"100571953","repetitive-transcranial-magnetic-stimulation-therapy-in-spinal-cord-injury-related-neuropathic-pain-100571953","NCT06726954","Repetitive Transcranial Magnetic Stimulation Therapy in Spinal Cord Injury Related Neuropathic Pain","Efficacy of Repetitive Transcranial Magnetic Stimulation Therapy in Neuropathic Pain Associated With Spinal Cord Injury; Randomized Controlled Trial","Inclusion Criteria:\n\nAged 18-75 years Physician-diagnosed spinal cord injury for at least 3-months Neuropathic pain for at least 3-months Pain not attributable to any other conditions\n\nExclusion Criteria:\n\n* Having an important comorbid disease such as severe heart disease (aortic stenosis, angina, hypertrophic cardiomyopathy, uncontrolled hypertension,arrhythmia, pacemaker)\n* Neurodegenerative disease\n* Epilepsy\n* History of antiepileptic drug use\n* Cognitive dysfunction\n* Lower extremity peripheral nerve injury\n* Increased intracranial pressure or uncontrolled migraine\n* Infection on the skin in the application area.\n* Having a brain lesion or a history of drug use that will affect the seizure threshold.\n\nAny TMS-related contraindications, for example:\n\n* Pacemaker\n* Metallic implant\n* Previous seizure\n* Psychiatric disorders (excluding depression and anxiety)\n* Malignancy\n* Current pregnancy",{"count":456,"type":22},63,[57],"The aim of our study is to investigate the effect of different protocols of high-frequency Repetitive Transcranial Magnetic Stimulation (rTMS) therapy added to the rehabilitation program on neuropathic pain,depression, quality of life and quality of sleep compared to each other and placebo group in participants with spinal cord injury.",[311,28],[461,462,28],"Transcranial Magnetic Stimulation","Spinal Cord Injury","2026-06-24",{"date":465,"type":37},"2026-06-26",{"date":467,"type":37},"2024-12-16",{"date":469,"type":22},"2026-12-30",{"name":471,"class":44},"Afyonkarahisar Health Sciences University",{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":476,"acronym":477,"eligibilityCriteria":478,"healthyVolunteers":391,"sex":18,"minAge":19,"maxAge":479,"enrollmentInfo":480,"targetDuration":4,"studyType":334,"phases":4,"briefSummary":482,"conditions":483,"keywords":4,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":485,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":489,"locationsCount":45},"100548372","the-prevalence-of-neuropathic-pain-pathophysiology-associated-with-ankle-fracture-100548372","NCT06420141","The Prevalence of Neuropathic Pain Pathophysiology Associated With Ankle Fracture","AFNP","Fracture Group:\n\nInclusion Criteria:\n\n1. 18-85 years old\n2. an isolated rotational ankle (AO\u002FOTA 44 types A-C) fracture that is treated operatively\n3. Abbreviated Injury Scale \\\u003C 3 for non-extremity body systems\n4. can speak, read, and understand English\n\nExclusion Criteria:\n\n1. treated for a chronic pain condition prior to their qualifying injury\n2. on a pain contract\n3. pathologic fracture\n4. Daily use of gabapentin or opiods prior to enrollment\n\nControl Group:\n\nInclusion Criteria:\n\n1. 18-85 years of age\n2. can speak, read, and understand English\n\nExclusion Criteria:\n\n1. Chronic pain or an ongoing acute pain condition\n2. Currently or have previously sustained a bone fracture\n3. Current Pain medication usage\n4. Any previous orthopaedic surgical procedures\n5. Must have been free of any surgeries for at least 5 years\n6. Peripheral neuropathy\n7. Individuals having had a major surgery or a major disease or condition, as determined by the PI, such as cardiovascular disease, metabolic disorders, renal disease, neurological disorders, or severe psychiatric conditions.","85 Years",{"count":481,"type":22},250,"This application addresses the Peer Reviewed Medical Research Program Investigator-Initiated Research Award FY21 W81XWH-22-CPMRP-IIRA area of Chronic Pain Management Research Program- The investigators will utilize subjects who have sustained ankle fractures and may develop chronic pain following bone union. No attempt will be made to affect the experimental outcome in the subjects. This study will adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of research.",[28],"2026-06-23",{"date":465,"type":37},{"date":487,"type":37},"2024-01-03",{"date":295,"type":22},{"name":490,"class":44},"Indiana University",{"id":492,"slug":493,"hasResults":12,"nctId":494,"briefTitle":495,"officialTitle":495,"acronym":496,"eligibilityCriteria":497,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":498,"targetDuration":4,"studyType":23,"phases":500,"briefSummary":501,"conditions":502,"keywords":504,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":508,"startDateStruct":509,"completionDateStruct":511,"leadSponsor":512,"locationsCount":45},"100535030","real-world-efficacy-of-evoke-closed-loop-spinal-cord-stimulation-cl-scs-therapy-in-chronic-pain-patients-ultra-100535030","NCT06246526","Real-World Efficacy of Evoke® Closed-loop Spinal Cord Stimulation (CL-SCS) Therapy in Chronic Pain Patients (ULTRA).","ULTRA","Inclusion Criteria:\n\nBe 18 years of age or older at the time of enrollment.\n\nDiagnosed with chronic, intractable pain of the trunk and\u002For limbs, which has been refractory to conservative therapy for a minimum of 6 months.\n\nSubject has a minimum Visual Analog Scale (VAS) score of 60 mm or higher (where 100 mm indicates the worst imaginable pain) at baseline.\n\nBe an appropriate candidate for the surgical procedures required in this study based on the clinical judgment of the implanting physician.\n\nBe willing and capable of giving informed consent.\n\nBe willing and able to comply with study-related requirements, procedures, and visits.\n\nExclusion Criteria:\n\nSubject is pregnant or nursing.\n\nHave a medical condition or pain in other area(s), not intended to be treated with SCS, that could interfere with study procedures, as determined by the Investigator.\n\nHave evidence of an active disruptive psychological or psychiatric disorder or other known condition significant enough to impact perception of pain, compliance of intervention, and\u002For ability to evaluate treatment outcomes.\n\nHave an existing drug pump and\u002For SCS system or another active implantable device such as a pacemaker, deep brain stimulator (DBS), or sacral nerve stimulator (SNS).\n\nHave prior experience with SCS.\n\nBe concomitantly participating in another clinical study.",{"count":499,"type":22},50,[57],"This observational, prospective data collection is designed to evaluate the efficacy of CL-SCS therapy in real-world patients suffering from chronic pain.",[503,60,28],"Pain",[505,506],"Saluda","Spinal Cord Stimulation","2026-06-22",{"date":484,"type":37},{"date":510,"type":37},"2024-01-30",{"date":295,"type":22},{"name":513,"class":44},"Saint Francis Hospital",{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":518,"acronym":519,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":521,"targetDuration":4,"studyType":23,"phases":522,"briefSummary":523,"conditions":524,"keywords":526,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":531,"startDateStruct":532,"completionDateStruct":534,"leadSponsor":536,"locationsCount":45},"100641680","evolution-of-different-sensitivity-levels-in-patients-with-chronic-neuropathic-pain-in-the-pelvi-perineal-region-after-treatment-with-high-concentration-capsaicin-patches-100641680","NCT07660510","Evolution of Different Sensitivity Levels in Patients With Chronic Neuropathic Pain in the Pelvi-perineal Region After Treatment With High-concentration Capsaicin Patches","CAPSASENS","Inclusion Criteria:\n\n* Men or women ≥ 18 years old.\n* Patients suffering from chronic pelvi-perineal neuralgia (\\>3 months) with a DN4 score ≥4 at the inclusion visit, with or without symptoms of central sensitization, and with an indication for topical treatment with high-concentration capsaicin patch (PCHC).\n* Patients who have signed the informed consent form for the study at the inclusion visit.\n* Women must meet one of the following criteria at the time of inclusion:\n* Use adequate contraceptive measures;\n* or Be postmenopausal (aged over 50 years with amenorrhea for at least 12 months after discontinuation of all exogenous hormonal treatments);\n* or (If aged under 50 years) have been amenorrheic for at least 12 months after discontinuation of exogenous hormonal treatments, with luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels consistent with postmenopausal levels;\n* or Have undergone irreversible surgical sterilization (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), with documentation of the procedure.\n\nExclusion Criteria:\n\n* Patients under guardianship, curatorship, or legal protection.\n* Pregnant or breastfeeding women.\n* Patients with contraindications to the use of the high-concentration capsaicin patch (PCHC): application on damaged skin, hypersensitivity to any of its components.\n* Patients simultaneously starting a treatment that may influence central sensitization (e.g., antidepressants, antiepileptics, psychotherapy, physical activity, transcutaneous electrical nerve stimulation).\n* Patients not affiliated with the French Social Security system.\n* Patients with insufficient cooperation and\u002For understanding to strictly comply with the protocol requirements.\n* Patients who have taken analgesics within the 12 hours prior to measurements.",{"count":363,"type":22},[57],"The primary objective of this study will be to demonstrate a change in pain sensitization parameters before and after the application of the high-concentration capsaicin patch.",[28,525],"Nociplastic Pain",[527,528,529,530],"Sensitization","8% capsaicin patch","Quantitative Sensory Testing","Temporal Summation",{"date":507,"type":37},{"date":533,"type":22},"2026-09-01",{"date":535,"type":22},"2028-03-01",{"name":537,"class":44},"Nantes University Hospital",{"id":539,"slug":540,"hasResults":12,"nctId":541,"briefTitle":542,"officialTitle":543,"acronym":4,"eligibilityCriteria":544,"healthyVolunteers":391,"sex":18,"minAge":19,"maxAge":545,"enrollmentInfo":546,"targetDuration":4,"studyType":23,"phases":548,"briefSummary":549,"conditions":550,"keywords":551,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":564,"startDateStruct":566,"completionDateStruct":568,"leadSponsor":570,"locationsCount":45},"100620882","phase-1-safety-tolerability-and-pharmacokinetics-of-asct-83-in-healthy-adults-100620882","NCT07363395","Safety, Tolerability, and Pharmacokinetics of ASCT-83 in Healthy Adults","A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASCT-83 Subcutaneous Injection in Healthy Adults","Inclusion Criteria:\n\nTo participate in the study, you must:\n\n* be medically healthy based on medical history, physical exam, labs, and ECG\n* be 18-64 years (inclusive)\n* at screening, have a body mass index (BMI) \\> 19 to \\\u003C 35 kg\u002Fm²\n* be willing and able to understand and voluntarily sign an informed consent\n* Female participants of childbearing potential (women who can become pregnant) must:\n\n  1. agree to follow the study contraceptive requirements from screening through 28 days after the final dose of study drug.\n  2. agree to undergo pregnancy testing, including a negative pregnancy test at screening and at admission.\n  3. agree not to donate ova (eggs) from screening through 28 days after the final dose of study drug.\n* Male participants must:\n\n  1. have a vasectomy greater than 6 months prior to screening or be willing to follow the contraceptive requirements from screening through 90 days after final study drug administration\n  2. agree to be willing to abstain from sperm donation from screening through 90 days after final study drug administration\n\nExclusion Criteria:\n\nYou cannot participate in the study if you:\n\n* are a study site staff, Alcamena employee or immediate family member, or have participated in another clinical trial within 30 days or 5 half-lives of a prior investigational product.\n* have evidence of liver disease or abnormal liver tests (ALT\u002FAST, Alk Phos, GGT, or bilirubin \\> ULN); positive hepatitis B or C serology (people with Gilbert syndrome may be included).\n* have a history of kidney disease, protein in the urine or reduced kidney function based on screening blood tests.\n* have a history of cancer with active disease, suspected relapse, treatment within 6 months, or ongoing therapy affecting immune, liver, or kidney function.\n* have a history of heart disease, including abnormal heart rhythm, heart attack, long QT syndrome, or abnormal heart rhythm findings on screening ECG, or a family history of sudden unexplained death.\n* are currently receiving medications that affect or suppress the immune system, including steroids given by any route.\n* have a known autoimmune condition (such as lupus, rheumatoid arthritis, sarcoidosis, or vitiligo), even if it is not being treated.\n* have a positive HIV test at screening or a history of immune deficiency.\n* have abnormal blood tests suggesting ongoing inflammation\n* have an active infection or is currently being treated for an infection.\n* have a skin condition that could interfere with study skin assessments (such as psoriasis).\n* are allergic or sensitive to the study drug or its ingredients.\n* have a history of alcohol or drug abuse or addiction within the past five years, have a positive drug or alcohol test at screening, or have smoked within one month before screening.\n* have a serious mental health condition, such as major depression, schizophrenia, severe anxiety, eating disorders, severe attention deficit disorder, personality disorders, or suicidal thoughts or behavior within the past five years that could affect safety or study participation.\n* have low blood pressure upon standing, defined as a significant drop in blood pressure when moving from lying down to standing during screening or baseline testing.\n* have abnormally low white blood cell counts or neutrophil counts, unless this finding is due to a known benign condition such as benign ethnic neutropenia.","64 Years",{"count":547,"type":22},72,[25],"The goal of this clinical trial is to learn if ASCT-83 is safe and well-tolerated and measure how ASCT-83 is absorbed, distributed, and eliminated from the body over time. The study will be conducted in healthy adults.\n\nThe main questions this study will answer are:\n\n* Is ASCT-83 safe at clinical doses?\n* Does ASCT-83 have side effects at clinical doses?\n* How is ASCT-83 absorbed, distributed, and eliminated from the body? Researchers will compare ASCT-83 to a placebo (a look-alike substance that contains no drug).\n\nThe study has two parts: participants in Part 1 will receive only one dose of ASCT-83 or placebo participants in Part 2 will receive one dose of ASCT-83 or placebo a day for 7 days. Participants will visit the clinic to take ASCT-83 or placebo, to receive health checkups and undergo health tests. Participants in Part 1 will spend 5 days\u002F4 nights in the clinic, participants in Part 2 will spend 11 days\u002F10 nights in the clinic. In addition, there will be up to 3 outpatient visits.\n\nThe results of this study will help determine safe dose levels and support the design of future clinical trials.",[28],[28,552,553,554,555,556,557,558,559,560,561,562,563],"Nerve Regeneration","Analgesic","CTDSP1 Inhibitor","REST (RE1-silencing transcription factor)","Macrocyclic Peptide","Target Engagement","First-in-Human (FIH)","SAD\u002FMAD","Healthy Volunteers","Pharmacokinetics (PK)","Diabetic Peripheral Neuropathy (DPN)","Peripheral Nerve Injury (PNI)",{"date":565,"type":37},"2026-06-16",{"date":567,"type":37},"2026-01-06",{"date":569,"type":22},"2026-12-01",{"name":571,"class":238},"Alcamena Stem Cell Therapeutics",{"id":573,"slug":574,"hasResults":12,"nctId":575,"briefTitle":576,"officialTitle":577,"acronym":4,"eligibilityCriteria":578,"healthyVolunteers":12,"sex":18,"minAge":579,"maxAge":4,"enrollmentInfo":580,"targetDuration":4,"studyType":23,"phases":581,"briefSummary":582,"conditions":583,"keywords":4,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":584,"lastUpdatePostDateStruct":585,"startDateStruct":586,"completionDateStruct":588,"leadSponsor":590,"locationsCount":45},"100523217","chronic-unilateral-lumbar-radicular-pain-100523217","NCT06092749","Chronic Unilateral Lumbar Radicular Pain","Effectiveness of Transgrade vs Interlaminar Epidural Steroid Injection for Chronic Unilateral Lumbar Radicular Pain","Inclusion Criteria:\n\n* \\> 6-month history of persistent pain in one leg with back pain.\n* Capable of giving informed consent.\n* Unsatisfactory response to conventional treatments including physical therapy or medications with a numeric rating scale (NRS) ≥ 5.\n\nExclusion Criteria:\n\n* Previous lumbar spinal surgery.\n* Myelopathy.\n* Rheumatoid disorders.\n* Psychiatric disorders\n* Bleeding or coagulation disorders","21 Years",{"count":55,"type":22},[57],"Chronic neuropathic lumbar pain is among one of the most widespread complaints of patients.Many approaches have been attempted to target chronic pain, with varying efficacy and risks. Transgrade (TG) epidural injection is a new technique using a Racz- Coudé needle for epidural access at a \"transgrade\" angle without requiring any specialized hardware or accessories. Interlaminar (IL) epidural steroid injection (ESI) is one of the procedures that involves the delivery of injectate to the epidural space through directing a needle between the laminae of two adjacent vertebrae.",[28],"2026-06-12",{"date":293,"type":37},{"date":587,"type":37},"2023-11-01",{"date":589,"type":22},"2026-07-31",{"name":591,"class":44},"Ain Shams University",{"id":593,"slug":594,"hasResults":12,"nctId":595,"briefTitle":596,"officialTitle":597,"acronym":598,"eligibilityCriteria":599,"healthyVolunteers":12,"sex":18,"minAge":600,"maxAge":601,"enrollmentInfo":602,"targetDuration":4,"studyType":23,"phases":604,"briefSummary":605,"conditions":606,"keywords":607,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":584,"lastUpdatePostDateStruct":611,"startDateStruct":612,"completionDateStruct":614,"leadSponsor":616,"locationsCount":298},"100515935","phase-3-analgesic-effectiveness-of-capsaicin-8-cutaneous-patch-in-children-100515935","NCT05997979","Analgesic Effectiveness of Capsaicin 8% Cutaneous Patch in Children","Analgesic Effectiveness of Capsaicin 8% Cutaneous Patch for the Treatment of Chronic Postsurgical or Post-traumatic Neuropathic Pain: a Randomized Placebo Controlled Study in Children Aged 12 to 17-y","CAPSAPED","Inclusion Criteria:\n\n* Children aged 12 to 17 years (lower age limit of 12 has been chosen to ensure NPSI full filling).\n* Male or female.\n* Persistent neuropathic pain more than 3 months after surgery or trauma despite treatment following recommendations.\n* Neuropathic pain is defined as a DN4 score equal to or greater than 3\u002F7 or 4\u002F10, and localized in a nerve territory explained by the surgery or the trauma.\n* Treatment, survey and follow up must be realized in an identified investigating center of the study\n* For patients of childbearing potential: use of an adequate method of contraception\\* during the course of the study through 48 hours after the last patch application (girls of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to the first patch application).\n\n  * Adequate contraception includes sexual abstinence, progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action, male or female condom with or without spermicide, cap, diaphragm or sponge with spermicide, combination of male condom with either cap, diaphragm or sponge with spermicide (double barrier methods)\n\nExclusion Criteria:\n\n* Intellectual deficiency not allowing full filling of NPSI.\n* Insufficient command of the French language to full fill NPSI and other evaluation tools.\n* Parents' refusal of consent.\n* Minor patients' opposition.\n* Underlying neurological disease.\n* Ongoing neurotoxic treatment.\n* Already treated by capsaicin.\n* Cutaneous lesion on pain area.\n* Patient presenting a pain area on the face, above the hairline of the scalp, and\u002For in proximity to mucous membranes\n* Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 of Qutenza SmPC.","12 Years","17 Years",{"count":603,"type":22},46,[213],"This study concerns children aged to 12 to 17-years with local chronic neuropathic pain after trauma or surgery.\n\nIt is a multicentric randomized controlled superiority trial in parallel arms :\n\n* experimental arm: Capsaicin 8% cutaneous patch\n* controlled arm : Hydrocolloid dressing\n\nTreatment with capsaicin application is realized at baseline, and repeated 3 months after the first patch application if needed.\n\nTolerance is assessed during each application and by phone call in following days until stop of cold need.\n\nEfficacy is assessed monthly by clinical consultation until the end of the study (month 4).",[28,60],[28,608,609,610],"Pediatric","Capsaicin","Randomized clinical trial",{"date":293,"type":37},{"date":613,"type":37},"2024-03-05",{"date":615,"type":22},"2028-07-05",{"name":617,"class":44},"University Hospital, Brest",{"id":619,"slug":620,"hasResults":12,"nctId":621,"briefTitle":622,"officialTitle":623,"acronym":624,"eligibilityCriteria":625,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":626,"targetDuration":4,"studyType":23,"phases":627,"briefSummary":628,"conditions":629,"keywords":631,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":635,"lastUpdatePostDateStruct":636,"startDateStruct":638,"completionDateStruct":640,"leadSponsor":642,"locationsCount":45},"100454358","phase-3-efficacy-of-an-intraoperative-periradicular-application-of-platelet-rich-fibrin-prf-on-the-intensity-of-residual-post-surgical-neuropathic-pain-after-a-surgery-for-disc-herniation-100454358","NCT05196503","Efficacy of an Intraoperative Periradicular Application of Platelet Rich Fibrin (PRF) on the Intensity of Residual Post-surgical Neuropathic Pain After a Surgery for Disc Herniation","Efficacy of Platelet Rich Fibrin in the Prevention of Residual Neuropathic Pain Following Disc Herniation Surgery","NeuroPRF","Inclusion criteria:\n\n* Patient, male or female, \\>18 years old at the time of signing informed consent;\n* Patient for whom a diagnosis of radiculopathy on lumbar disc herniation has been made, and for whom surgery has been scheduled in the Neurosurgery department;\n* Patient affiliated to a social security health insurance scheme;\n* Patient able to understand the objectives and risks of research and to give informed, dated and signed consent;\n* Patient having been informed of the results of the prior medical examination;\n* Women of childbearing age provided that a negative blood pregnancy test is recorded at the inclusion visit and effective contraception used throughout the study.\n\nExclusion criteria:\n\n* Patient with a history of lumbar spinal surgery (multiple herniated discs, herniated disc other than lumbar);\n* Patient with HIV, active cancer, HBV, HCV (verified by interview);\n* Patient on long-term systemic corticosteroid therapy;\n* Patient with an ASA score \\> 3 during the consultation with the anesthesiologist;\n* Inability to give the patient informed information (patient in an emergency or life-threatening situation, difficulties in understanding);\n* Patient in exclusion period (determined by a previous or ongoing study);\n* Subject under safeguard of justice;\n* Subject under curatorship;\n* Pregnancy;\n* Breastfeeding.",{"count":107,"type":22},[213],"The prevalence of post-surgical lumbar neuropathic radiculopathy is approximately 30%. Poor response to the treatments recommended for neuropathic pain, namely antidepressants and\u002For gabapentinoids, requires the development of new techniques to prevent this chronic pain. Certain well-tolerated techniques, such as the administration of plasma enriched with platelets and fibrin (PRF), are increasingly used in regenerative medicine for their anti-inflammatory and analgesic properties. Thus, a periradicular intraoperative application of PRF may have an analgesic effect on the intensity of residual postsurgical neuropathic pain after disc herniation surgery.",[28,630],"Chronic Postsurgical Pain",[287,632,633,634],"Chronic postsurgical pain prevention","Intraoperative platelet rich fibrin","Disc herniation surgery","2026-06-05",{"date":637,"type":37},"2026-06-08",{"date":639,"type":37},"2022-02-23",{"date":641,"type":22},"2028-01",{"name":643,"class":44},"University Hospital, Strasbourg, France",{"id":645,"slug":646,"hasResults":12,"nctId":647,"briefTitle":648,"officialTitle":649,"acronym":4,"eligibilityCriteria":650,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":651,"targetDuration":4,"studyType":23,"phases":653,"briefSummary":654,"conditions":655,"keywords":657,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":660,"lastUpdatePostDateStruct":661,"startDateStruct":663,"completionDateStruct":664,"leadSponsor":666,"locationsCount":45},"100642849","development-of-a-pain-rehabilitation-program-for-chronic-pain-after-sci-100642849","NCT07634796","Development of a Pain Rehabilitation Program for Chronic Pain After SCI","Feasibility of a New Digital Pain Rehabilitation Program for People With SCI","Inclusion Criteria:\n\n* two years since injury\n* Stable pain medication?\n\nExclusion Criteria:\n\n* severe cognitive impairment\n* Alcohol or drug abuse\n* does not understand Swedish",{"count":652,"type":22},32,[57],"Pain rehabilitation programs are essential for optimal treatment of chronic pain and are usually based on the biopsychosocial model. This is, however, not standard care for people with chronic pain after a spinal cord injury (SCI) due to a biomedical focused perspective of SCI and lack of adapted programs.\n\nThe aims of this feasibility study:\n\n1. Develop a new digital pain rehabilitation program, adapted for the needs of people living with an SCI.\n2. To investigate the feasibility and acceptability of a new digital pain rehabilitation program.",[311,60,28,656,337],"Interprofessional Team Collaboration",[658,659],"participatory design","feasibility study","2026-06-02",{"date":662,"type":37},"2026-06-09",{"date":141,"type":22},{"date":665,"type":22},"2027-09",{"name":667,"class":44},"Umeå University"]